Agenda for November 2026 Mental Health Advisory Committee meeting

Meeting agenda Medicines

Information on what the Mental Health Advisory Committee will be considering at its upcoming meeting in November 2026.

Matters Arising

Reviewing the access criteria for medicines for attention deficit hyperactivity disorder (ADHD)

The Committee will discuss current special authority criteria for medicines used for ADHD and consider the need for alterations.

Applications

Guanfacine (branded as Intuniv) for ADHD

The Committee will discuss an application for guanfacine for people with ADHD.

Application for gaunfacine(external link)

Guanfacine (branded as Intuniv) for ADHD traits in autism spectrum disorder (ASD)

The Committee will discuss an application for guanfacine for people with Autism Spectrum Disorder (ASD) who experience symptoms of ADHD.

Application for gaunfacine (for ADHD with ASD)(external link)

Guanfacine (branded as Intuniv) for ADHD traits in people with Prader-Willi syndrome (PWS)

The Committee will discuss an application for guanfacine for people with Prader-Willi syndrome (PWS) who experience symptoms of ADHD.

Application for gaunfacine (for ADHD with PWS)(external link)

Naltrexone hydrochloride (branded as Naltraccord) for alcohol use disorder

The Committee will discuss an application to amend the Special Authority criteria for naltrexone hydrochloride for people with alcohol dependence. This application seeks to widen access by amending the special authority criteria to include primary healthcare providers.

Application for naltrexone hydrochloride(external link)

Clozapine intramuscular (branded as Clozapine) for treatment refractory psychotic disorder

The Committee will discuss an application for intramuscular clozapine for people with treatment resistant psychotic disorders.

Application for Clozapine intramuscular(external link)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.